Entrada Therapeutics Stock Target Price and Analyst Consensus
| TRDA Stock | USD 18.80 0.75 4.16% |
The current analyst and expert consensus on Entrada Therapeutics is Strong Buy, with 4 strong buy opinions. The current projected Entrada Therapeutics target price consensus is 25.00 with 5 analyst opinions. Check out Macroaxis Advice on Entrada Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.The most common way Entrada Therapeutics analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview Entrada Therapeutics executives and customers to further validate their buy or sell advice. Note, the total number of analysts currently providing their opinion is not significant to determine adequate consensus on Entrada Therapeutics. We strongly encourage you to use your own analysis of Entrada Therapeutics to validate this buy or sell advice. Entrada Therapeutics buy-or-sell recommendation module provides average expert sentiment on the projected Entrada Therapeutics target price to derive its highest and lowest estimates based on projected price volatility of 3.3369.
Lowest Forecast 22.75 | Highest Forecast 27.75 | Target Price 25 |
Entrada |
It's important to approach Entrada Therapeutics' target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize Entrada Therapeutics price targets
Entrada Therapeutics' stock target price is an estimate of its future price, usually made by analysts. Using Entrada Therapeutics' target price to determine if it is a suitable investment can be done through the following steps:- Look at Entrada Therapeutics' target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if Entrada Therapeutics' stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional Entrada Therapeutics Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Entrada Therapeutics is a key component of Entrada Therapeutics valuation and have some predictive power on the future returns of a Entrada Therapeutics.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Entrada Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Entertainment Invested over 90 shares | |
 | Macroaxis Index Invested few shares | |
 | Hedge Favorites Invested over 60 shares | |
 | Banking Invested over 20 shares | |
 | FinTech Invested over 40 shares | |
 | Investor Favorites Invested few shares | |
 | Driverless Cars Invested few shares | |
 | Macroaxis Picks Invested over 30 shares | |
 | Business Services Invested few shares | |
 | Manufacturing Invested over 30 shares | |
 | Momentum Invested few shares |
Check out Macroaxis Advice on Entrada Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Please note, the presentation of Entrada Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Entrada Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Entrada Therapeutics' management manipulating its earnings.